06 Jan 2025 by admin in UncategorizedComments Adcentrx Therapeutics Announces First Patient Dosed in the Phase 1a/b Study of ADRX-0405, a Potential First-in-Class ADC Targeting STEAP1 for the Treatment of Advanced Solid Tumors
19 Dec 2024 by admin in UncategorizedComments Adicet Bio Announces First Patient Dosed in the Phase 1 Clinical Trial of ADI-270 in Metastatic/Advanced Clear Cell Renal Cell Carcinoma
18 Dec 2024 by admin in UncategorizedComments Adicet Bio Appoints Julie Maltzman, M.D. as Chief Medical Officer
10 Dec 2024 by admin in UncategorizedComments NextCure Announces Acceptance of IND Application for LNCB74
26 Nov 2024 by admin in UncategorizedComments Oricell Therapeutics Receives China NMPA IND Clearance for MSLN/Claudin 18.2 Dual CAR-T Therapy for Solid Tumors
26 Nov 2024 by admin in UncategorizedComments Adcentrx Therapeutics Announces FDA Clearance of Investigational New Drug Application for ADRX-0405, a Potential First-in-Class ADC Targeting STEAP1 for the Treatment of Advanced Solid Tumors
20 Nov 2024 by admin in UncategorizedComments Avenzo Therapeutics Announces Appointment of Patrick Machado, J.D. to Board of Directors as Independent Director
19 Nov 2024 by admin in UncategorizedComments Preclinical Data Demonstrates Anti-Siglec-15 Treatment Enhanced Generation of Quality Bone with Better Mechanical Properties in Mice with Moderate-to-Severe Osteogenesis Imperfecta
18 Nov 2024 by admin in UncategorizedComments Adicet Bio Announces First Lupus Nephritis Patient Dosed in Phase 1 Clinical Trial of ADI-001 in Autoimmune Diseases